Merus N.V.

Netherlands · Research

Merus N.V. is a clinical-stage biotechnology company based in Utrecht, The Netherlands, founded in 2003. The company specializes in developing innovative multispecific antibody therapeutics for cancer treatment, utilizing its proprietary Multiclonics® platforms, which include bispecific (Biclonics®) and trispecific (Triclonics®) antibodies. These antibodies are designed to bind multiple targets simultaneously, enhancing their anti-cancer effects. Merus is dedicated to discovering and developing novel therapeutics that leverage the immune system to improve the lives of cancer patients. Its product pipeline features several clinical-stage candidates, with petosemtamab as the lead asset, targeting EGFR and LGR5. This candidate has shown promising clinical activity in head and neck squamous cell carcinoma and is currently undergoing phase 3 trials. The company also targets various cancers, including advanced non-small cell lung cancer and metastatic colorectal cancer, among others. With a global presence and a team of over 260 professionals, Merus is committed to advancing its oncology therapeutics and enhancing patient outcomes.